Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity.

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Hepatitis E virus (HEV) infections are increasingly reported in developed countries, necessitating better disease management and vaccine development.
• Understanding HEV pathogenesis, virology, and host immune responses is key to achieving protective immunity.

Purpose of the Study:

• To review current knowledge on HEV virology, neutralization sites, and host immune responses.
• To discuss the role of recombinant virus-like particles (VLPs) in vaccine development.
• To summarize diagnostic markers and the progress of HEV vaccine candidates.

Main Methods:

• Literature review of HEV virology, immunology, and vaccine research.
• Analysis of diagnostic markers for HEV infection (viral RNA, IgM, IgG, IgG avidity).
• Evaluation of preclinical and clinical trial data for HEV vaccine candidates.

Main Results:

• Recombinant VLPs mimic protective epitopes and elicit immune responses in preclinical and clinical studies.
• Four key markers aid in diagnosing HEV infection, particularly acute cases.
• Two HEV vaccine candidates demonstrate good tolerability, immunogenicity, and efficacy, with one licensed in China.

Conclusions:

• Significant progress has been made in understanding HEV and developing vaccines.
• Further research is needed to address remaining challenges and ensure widespread access to new HEV interventions.